173 related articles for article (PubMed ID: 1748061)
21. Influence of glucose, fructose and aldose reductase inhibition on retinal sorbitol metabolism.
Naeser P; Brolin SE
Acta Ophthalmol (Copenh); 1991 Oct; 69(5):591-5. PubMed ID: 1776411
[TBL] [Abstract][Full Text] [Related]
22. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A
J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059
[TBL] [Abstract][Full Text] [Related]
23. Polyol pathway and protein kinase C activity of rat Schwannoma cells.
Kamiya H; Nakamura J; Hamada Y; Nakashima E; Naruse K; Kato K; Yasuda Y; Hotta N
Diabetes Metab Res Rev; 2003; 19(2):131-9. PubMed ID: 12673781
[TBL] [Abstract][Full Text] [Related]
24. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
[TBL] [Abstract][Full Text] [Related]
25. The role of sorbitol pathway and treatment effect of aldose reductase inhibitor ONO2235 in the up-regulation of cardiac M2-muscarinic receptors in streptozotocin-induced diabetic rats.
Liu TP; Juang SW; Cheng JT; Tong YC
Neurosci Lett; 2005 Jul 22-29; 383(1-2):131-5. PubMed ID: 15936525
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of aldose reductase in human erythrocytes by vitamin C.
Vincent TE; Mendiratta S; May JM
Diabetes Res Clin Pract; 1999 Jan; 43(1):1-8. PubMed ID: 10199583
[TBL] [Abstract][Full Text] [Related]
27. Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism. Implications for diabetic retinopathy.
Van den Enden MK; Nyengaard JR; Ostrow E; Burgan JH; Williamson JR
Invest Ophthalmol Vis Sci; 1995 Jul; 36(8):1675-85. PubMed ID: 7601647
[TBL] [Abstract][Full Text] [Related]
28. Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil.
Kato K; Nakayama K; Mizota M; Miwa I; Okuda J
Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1540-5. PubMed ID: 1934175
[TBL] [Abstract][Full Text] [Related]
29. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
30. Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients.
Hamada Y; Kitoh R; Raskin P
Diabetes; 1991 Oct; 40(10):1233-40. PubMed ID: 1936586
[TBL] [Abstract][Full Text] [Related]
31. Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
Hayashi R; Hayakawa N; Makino M; Nagata M; Kakizawa H; Uchimura K; Hamada M; Aono T; Fujita T; Shinohara R; Nagasaka A; Itoh M
Diabetes Care; 1998 Apr; 21(4):672-3. PubMed ID: 9571366
[No Abstract] [Full Text] [Related]
32. Sorbitol metabolism in the retina, optic nerve, and sural nerve of diabetic rats treated with an aldose reductase inhibitor.
Naeser P; Brolin SE; Eriksson UJ
Metabolism; 1988 Dec; 37(12):1143-5. PubMed ID: 3143049
[TBL] [Abstract][Full Text] [Related]
33. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
Stribling D; Mirrlees DJ; Harrison HE; Earl DC
Metabolism; 1985 Apr; 34(4):336-44. PubMed ID: 3920474
[TBL] [Abstract][Full Text] [Related]
34. Influence of interindividual variability of aldose reductase protein content on polyol-pathway metabolites and redox state in erythrocytes in diabetic patients.
Hamada Y; Nishimura C; Koh N; Sakakibara F; Nakamura J; Tanimoto T; Hotta N
Diabetes Care; 1998 Jun; 21(6):1014-8. PubMed ID: 9614624
[TBL] [Abstract][Full Text] [Related]
35. Urinary sorbitol measurement and the effect of an aldose reductase inhibitor on its concentration in the diabetic state.
Nakano I; Tsugawa T; Shinohara R; Watanabe F; Fujita T; Nagata M; Kato T; Himeno Y; Kobayashi T; Fujiwara K; Nagata M; Itoh M; Nagasaka A
J Diabetes Complications; 2003; 17(6):337-42. PubMed ID: 14583178
[TBL] [Abstract][Full Text] [Related]
36. Role of sorbitol in the up-regulation of urinary bladder M(2) muscarinic receptors in streptozotocin-induced diabetic rats.
Tong YC; Chin WT; Cheng JT
Neurourol Urodyn; 2002; 21(2):154-9. PubMed ID: 11857669
[TBL] [Abstract][Full Text] [Related]
37. Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860).
Asano T; Saito Y; Kawakami M; Yamada N; Sekino H; Hasegawa S;
J Diabetes Complications; 2004; 18(6):336-42. PubMed ID: 15531183
[TBL] [Abstract][Full Text] [Related]
38. Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant.
Hotta N; Nakamura J; Sakakibara F; Hamada Y; Hara T; Mori K; Nakashima E; Sasaki H; Kasama N; Inukai S; Koh N
Am J Physiol; 1997 Nov; 273(5):E965-71. PubMed ID: 9374683
[TBL] [Abstract][Full Text] [Related]
39. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M
Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
[TBL] [Abstract][Full Text] [Related]
40. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y
Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
